{"id":"787298132601-52","name":"Daval International Limited","registrationDate":"2018-09-17T15:55:46.275+02:00","category":2,"subCategory":3,"legal":"Corporation","web":"http://www.davalinternational.com","country":"United kingdom","headAddress":"Daval International Ltd","headCity":"London","headPostCode":"SW7 4ES","headPhone":"(44)84 51 30 30 14","boss":"Kevin Norville","bossTitle":"Mr","bossPosition":"CEO","membersCount":3,"membersFTE":"1.25","membership":"The Association of the British Pharmaceutical Industry (ABPI) – abpi@apbi.org.uk","memberOrga":"","goal":"Daval International Limited is a UK-based biotechnology company formed in 2000 and focused on the development and delivery of novel and distinctive treatments for serious unmet medical conditions. Daval was accepted as a member of the UK’s Association of the British Pharmaceutical Industry (ABPI) in December 2007 and adheres to the APBI's Code of Practice. Daval has developed AIMSPRO, a potent, anti-inflammatory, natural, biological therapy that has proven capacity to reduce inflammation. Daval believes that, in AIMSPRO, they may have the next efficacious Alzheimer's disease medication which has a decade-long proven safety record in human patients.","acronym":"","interests":"Public Health, Research and innovation","euInitiatives":"Daval International will be meeting with various EU Institutions and agencies to seek clarity on EU initiatives, policies and legislation relating to their project. This will include issues surrounding the conducting of clinical trials for Alzheimer's disease.","lastUp":"2018-09-17T16:09:53.723+02:00","customers":"","costAbsolu":"","costRange":"50000-99999","turnoverAbsolu":0,"turnoverRange":""}